Introduction
Juvenile myoclonic epilepsy (JME) is one of the most common types of genetic generalized epilepsy.
1 JME is characterized by adolescent onset, infrequent absence seizures, awakening myoclonic seizures and generalized tonic-clonic (GTC) or clonic-tonicclonic (CTC) seizures. Two JME-causing genes have been identified and their associations with JME have been replicated. These genes include GABRA1 on chromosome 5q34q35 2, 3 and EFHC1 on chromosome 6p12. 4 In another study, 9% of JME patients from
Honduras and Mexico and 3% of JME patients from Japan were found to carry heterozygous missense, nonsense and deletion frameshift mutations in the EFHC1 gene. 5 Here, we report the presence of three additional novel EFHC1 heterozygous missense mutations in a new cohort of forty-one Mexican JME patients. We also compared the presence of the JME subsyndromes and the persistence of seizures in JME patients with and without EFHC1 mutations.
Methods

Patient and family samples
Forty-one Mexican JME patients were recruited for the present study from the National Institute of Neurology and Neurosurgery (NINN) in Mexico City. The diagnosis of JME was established by two epileptologists using the following inclusion criteria. (a) The onset of myoclonic seizures presented between 8 and 20 years of age. The myoclonic seizures experienced by the patient were characterized Seizure 21 (2012) 550-554 by short, bilateral, symmetrical or asymmetrical muscular contractions. These seizures predominantly manifested in the shoulders and arms and were less frequently observed in the legs. There was no evidence of loss of consciousness with the seizures. (b) Interictal EEG of the patient showed diffuse, bilateral, symmetrical and synchronous 3-6 Hz spike, polyspike and slow wave complexes. (c) The presence of GTC or CTC seizures at the onset or over the course of the disease. (d) The patient was required to have a normal neurological exam. (e) The patient was required to have normal brain neuroimaging studies, such as computed tomography and/or magnetic resonance imaging, at the onset of symptoms.
The exclusion criteria for patients in the study included: (a) history of symptomatic seizures; (b) family history of progressive myoclonic epilepsy; (c) evidence of a progressive neurological disease that could cause epilepsy and (d) presence of simple partial or complex seizures. 5 When EFHC1 mutations were identified in the patients, blood was drawn from the proband's family members for DNA analysis. The family members also underwent EEG. Informed consent was obtained from all participants, and the study was approved by the Bioethics Committee of the NINN. We also obtained the donated blood samples of 100 anonymous individuals without a history of seizures from the NINN blood bank. These samples were tested as ethnically matched healthy controls. Next, we categorized each of the forty-one JME patients into one of the four previously described JME subsyndromes. 1 Comparisons of the JME phenotypes and the persistence of seizures between patients with and without EFHC1 mutations were made using x 2 or Fisher's exact test. The data were analyzed using SPSS version 17.
DNA sequencing
Peripheral venous blood was drawn from forty-one JME patients and 100 healthy controls. Blood was also drawn from seven family members of the probands with EFHC1 mutations. DNA was extracted from each blood sample using the QIAmp DNA blood Mini Kit (QIAGEN, Valencia, CA, USA). The exons of EFHC1 were amplified using the primers and polymerase chain reaction (PCR) conditions described by Suzuki et al. 4 The PCR products were then purified and sequenced using the Big Dye Terminator sequencing reactions in an automated DNA sequencer (ABI PRISM 3130 Applied Biosystems, Foster City, CA). The identified variants were sequenced at least twice in both the forward and reverse directions.
Results
Clinical characteristics
In our cohort of 41 JME patients, 25 (61%) were female. The average age at onset of epilepsy was 14.24 years (range 5-20 years). Twentyone subjects (51.2%) had a positive family history of epilepsy. The majority (33 or 80%) of the patients met the criteria for classic JME, four patients (10%) had CAE that evolved into JME, two patients (5%) met the criteria for JME with adolescent-onset pyknoleptic and two patients (5%) met the criteria for JME with astatic seizures.
Mutation analysis
The three new mutations (7.3%) identified in this cohort of JME patients were heterozygous missense mutations. They have not been previously reported in the single nucleotide polymorphism database (SNPs). All three of the novel mutations are located in exon 3 of the EFHC1 gene. The first identified mutation, 352C>T, changes the Myoclonin1 protein by substituting cysteine for arginine at amino acid position 118 (R118C). This mutation was also found in the patient's affected father and brother (Fig. 1A) . The second mutation, 544C>T, substitutes lysine for arginine at position 182 of the protein (R182L). The patient's asymptomatic father, who had a normal EEG, also carried the same mutation (Fig. 1B) . The third mutation, 458G>A, replaces an arginine with glutamine at position 153 of the protein (R153Q). The patient's asymptomatic father also carried this mutation (Fig. 1C) . None of these mutations were found in the controls.
The three identified missense mutations, R118C, R153Q and R182C, are found in exon 3. In silico analysis shows that the affected region includes part of the first DM10 domain (position 93-198) (Figs. 2 and 3) and resides in an evolutionary conserved amino acid sequence (EMBL Clustal W2). These mutations were predicted to have damaging effects on function by the Polyphen program. The three mutations received PSIC scores of 3.241, 2.278, and 2.124, respectively.
The following previously described polymorphisms were also identified: G545A was found in three patients; G475T was found in four patients; G881A was found in one patient; and F1058C and A1855C were found in two patients. None of these polymorphisms appear to predispose individuals to JME. 4 
Discussion
In total, 674 SNPs variants have been identified in the EFHC1 gene. They can be found in the human genome database (GENOME 1000). Of these variants, 132 are located in exon regions. Prior to our present report, 22 of these exon variants (18 missense variants, one nonsense variant, one three-base deletion variant in the promoter region, one variant in the 3 0 UTR and one deletion/frameshift variant) were considered to be heterozygous pathogenic mutations that were transmitted as autosomal dominant traits. This assumption was based on several pieces of evidence. (1) Some studies have reported the segregation of EFHC1 mutations with the incidence of epilepsy and EEG polyspike waves. These studies were based on analyses of affected family members across 2-4 generations of 13 JME families from Mexico, Honduras, Japan and Italy. These findings suggest that EFHC1 is a Mendelian gene that strongly predisposes individuals to epilepsy in these rare families. [4] [5] [6] (2) Additionally, EFHC1 mutations were found to be transmitted by unaffected parents to 12 JME singletons in studies conducted in Mexico, Austria, Honduras, Tennessee (USA) and Japan. These findings support the view that these mutations constitute an autosomal dominant trait with incomplete penetrance. 4-8 (3) Furthermore, the presence of myoclonic and GTC seizures in efhc1À/À mice has been reported and replicated. This result proves that the loss of EFHC1 function alone is sufficient to cause epilepsy. 9 Furthermore, the specific EFHC1 missense mutations of EFHC1 that segregate in families and are found in singletons may potentially be pathogenic. The changes of the domain sites at which EFHC1 mutations occur have potential deleterious functional effects on the encoded myoclonin1 protein, as predicted by ''in silico analysis''. Further, the identified EFHC1 mutations are often located in evolutionarily conserved domains. Finally, functional studies of the effect of the individual missense mutations in vitro indicate that the mutations are pathogenic. For instance, the overexpression of EFHC1 in mouse hippocampal primary neuronal cultures induced apoptosis. This apoptosis was significantly decreased in five types of hippocampal cells each with a distinct EFHC1 missense mutation. These missense mutations were double heterozygous 229C>A and 662>A; 685T>C; 628G>A; 757G>T; and 545G>A. 4 In addition, patch clamp analysis of HEK cell cultures revealed that EFHC1 specifically increased R-type Ca 2+ currents. These currents were also shown to increase apoptotic processes. The increased R-type Ca 2+ currents were partially reversed by each of five tested EFHC1 missense mutations. 4 Analyses of the contribution of the EFHC1 variants to ''epilepsy risk'' have also been performed. Bai et al. 10 asked if the coding SNPs of EFHC1 contributed to the development of epilepsy as minor susceptibility alleles with small genetic displacements. This study tested an oligogenic or polygenic hypothesis of epilepsy susceptibility. Their study included 130 unrelated JME patients and 352 family members. No statistically significant differences between the JME probands and controls were found in the association analysis. No transmission disequilibrium was found for the four tested SNPs (rs3804506, rs3804505, rs1266787, rs17851770) in the family-based association analysis. 10 Thus, in this small cohort, these four EFHC1 SNPs did not confer susceptibility for JME. To date, the cosegregation of Myoclonin1/EFHC1 mutations with JME has been reported in 13 JME families. We have identified an additional Mexican family in which the R118C mutation segregated with the three affected members in two different generations.
The two other mutations that we have identified, R182L and R152Q, were transmitted by unaffected parents to 2 unrelated singletons. These mutations can be added to the 12 currently known singleton EFHC1 mutations in the literature. The heterozygous missense mutations reported here should be considered putative mutations because functional studies of the effects of these specific mutations have not yet been performed. We originally screened 41 new JME patients to confirm the frequency of Myoclonin1/EFHC1 mutations in Mexican families. We wished to perform this analysis in our own genetics laboratory, independent of the Los Angeles epilepsy genomics/genetics laboratories. It is too early to tell how many of the remaining 119 EFHC1 exonic variants reported in GENOME 1000 are pathogenic and how frequently these mutations occur in various populations. However, as described previously and in this report, EFHC1 mutations were present in 7% to 9% of JME patients that presented to the Neurology/Epilepsy Clinics of Mexico, Los Angeles and Honduras. 4, 5 To date, the GENESS consortium has described fourteen different EFHC1 mutations in unrelated JME families, including the three mutations described in this paper. Most of these mutations were also found in our Mexican sample. This result suggests that EFHC1 mutations are frequently present in Mexican patients with JME. 4, 5 In addition to the mutations found in the Mexican JME families, heterozygous missense EFHC1 mutations have also been described in Caucasian JME families from Italy, 6 Austria, 7 and
Tennessee, USA. 8 Interestingly, EFHC1 mutations have been identified in individuals with different idiopathic epilepsies and one type of temporal lobe epilepsy. These results suggest that the EFHC1 mutations may be pleiotropic and may be expressed as various epilepsy phenotypes. 7 Currently, EFHC1 mutations have been primarily identified in JME probands. They are rarely found in probands with juvenile absence and pure grand mal seizures. However, EFHC1 mutations are found in the affected family members of individuals with JME, pure grand mal seizures, childhood pyknoleptic absence seizures, juvenile absence seizures and adolescent astatic seizures. [4] [5] [6] [7] The identified EFHC1 mutations include deletions, insertions and frameshifts that give rise to stop codons. However, genes that encode loss of function proteins are present in normal healthy individuals. Approximately 100 genuine loss of function variants and 20 completely inactivated genes have been estimated to exist in the human genome. 11 Thus, the identified mutations must undergo functional analysis before they can be considered to cause epilepsy. This requirement is true for the missense and stop codon mutations alike. Furthermore, the presence of incomplete penetrance may explain the reason that the patients' fathers in families B and C remain asymptomatic and have normal EEGs despite carrying EFHC1 mutations. 4 Several lines of evidence point to the mechanisms through which the impaired functions or loss of function mutations of EFHC1 may cause epilepsy. In vitro studies of mitosis in various cell lines as well as in vivo studies in Drosophila melanogaster, show that EFHC1 is a microtubule-associated protein. EFHC1 co-localizes with the mitotic spindle, especially with the spindle poles and midbody. 12 In the in vitro experiments, the loss of EFHC1 function disrupts mitotic spindle organization, impairs M phase progression, prevents microtubule bundling and increases apoptosis. 12 Experiments in the developing rat cortex have shown that the knockdown of EFHC1 by ex vivo and in utero electroporation with iRNA disrupts projection neuroblast radial migration. Several steps of neurogenesis are affected to achieve this effect. The cell division, mitosis and cell cycle exit of cortical progenitors are disrupted. Additionally, the organization of the radial glia scaffold and the locomotion of postmitotic neurons in the intermediate zone are disturbed. The abnormalities in all of these steps contribute to the neuronal migration defects. 13 In vivo studies of Drosophila melanogaster knocked out for the Defhc1.1 gene, a homolog of EFHC1, have also been performed. The KO mutants exhibit increased synaptic bouton proliferation, overgrowth of dendritic arbors and augmented neurotransmitter release. Transfection of the mutant with Defhc1.1 rescues synaptic bouton proliferation, decreases dendritic elaboration and augments neurotransmitter release. 14 Based on these in vitro and in vivo functional studies, loss of function mutations in the Myoclonin1/EFHC1 gene may induce epileptogenesis by disturbing microtubule cytoskeleton dynamics, increasing microtubule bundling, increasing synaptic bouton proliferation and dendritic arborization and augmenting neurotransmitter release. The disturbance of these processes may ultimately cause seizures. Because Myoclonin1/EFHC1 also regulates neuronal migration during cortical development, the disruption of projection neuroblast migration may also result in cortical and subcortical microdysgenesis and lead to the establishment of anatomical epileptogenic networks.
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Conclusions
We report that the R118C heterozygous mutation in the EFHC1 gene cosegregates with three affected members across two generations in one family. Our study also observed two other novel mutations, R182L and R152Q. These mutations were transmitted by asymptomatic fathers to unrelated singletons. This result suggests that these autosomal dominant EFHC1 mutations exhibit incomplete penetrance. Until functional studies show the deleterious effects of these mutations on the Myoclonin1 protein, however, they remain putative risk alleles for epilepsy.
